Table 4.

Recommendations for palivizumab prophylaxis in children with CHD.

(i) ≤24 months of age with hemodynamically significant cyanotic CHD
(a) Infants receiving medication to control congestive heart failure
(b) Infants with moderate-to-sever pulmonary hypertension
(c) Infants with cyanotic heart disease
(ii) Initiate 15 mg/kg of palivizumab prophylaxis monthly during RSV season (typically November through March in North America)
(iii) Give additional dose of palivizumab 15 mg/kg in patients who require cardiopulmonary bypass for a surgical procedure and will continue to need prophylaxis as soon as they are medically stable

Source: [41].